<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05095181</url>
  </required_header>
  <id_info>
    <org_study_id>1188</org_study_id>
    <nct_id>NCT05095181</nct_id>
  </id_info>
  <brief_title>To Study the Effects of Host Genetic Factors on Liver Cirrhosis</brief_title>
  <official_title>Preventive and Personalized Medicine (2021-2023)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asfendiyarov Kazakh National Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asfendiyarov Kazakh National Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify genetic determinants of susceptibility to liver&#xD;
      cirrhosis . It will assist in predicting individual risks of disease progression and would&#xD;
      help to clarify pathophysiologic mechanisms of liver cirrhosis .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 23, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>genotyping for the SNP associated with liver cirrhosis</measure>
    <time_frame>1 year</time_frame>
    <description>Genotype frequency of SNP in the study genes of participants and control participants.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Experimental group:</arm_group_label>
    <description>patients with liver cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>patients without liver cirrhosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SNP analysis of the DNA</intervention_name>
    <description>SNP analysis of the DNA obtained from peripheral blood sample</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group:</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        KAZAKH POPULATION&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  hepatitis B&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  the casual aget of liver disease is not viral infection, such as alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bibigul Saparbekovna, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>JSC &quot;National Scientific Center of Surgery named after A.N. Syzganova &quot;</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bibigul Saparbekovna, PhD</last_name>
    <phone>+77075001190</phone>
    <email>fakhradiyev.i@kaznmu.kz</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asfendiyarov Kazakh National Medical University</investigator_affiliation>
    <investigator_full_name>Ildar Fakhradiyev</investigator_full_name>
    <investigator_title>Head of the Laboratory of Experimental Medicine</investigator_title>
  </responsible_party>
  <keyword>SNP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

